Brought to you by 
Lilly acquires AME for stock and cash
12 Feb 2004
Executive Summary
To power up its biotech effort, Lilly has agreed to acquire Applied Molecular Evolution (technology for optimizing large molecules) for about $400mm. AME stockowners will receive $18 for each outstanding share (a 48% premium), and they may elect to take it in cash or stock (number of shares to be based on Lilly's market price when the deal closes), with the stipulation that 80% of the total payment must be in stock.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly acquires AME for stock and cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice